

## Therapie chronischer Schmerzen: Update

### Teil 2: Opiat-Analgetika, adjuvante Medikamente und Wirkstoffe mit schmerzmodulierenden Eigenschaften

### Treatment des douleurs chroniques: update

### 2<sup>e</sup> partie: analgésiques opioïdes, médicaments adjuvants et substances à propriétés modulatrices de la douleur

### Literatur / Références

- 51 Machelska H, Stein Ch. Immune mechanism in pain control. Anesth Analg. 2002;95:1002–8.
- 52 Mathew B, Lennon FE, Siegler J, Mirzapoiazova T, Mambetsariev N, Sammani S, Gerhold L, et al. The novel role of the mu opioid receptor in lung cancer progression: a laboratory investigation. Anest Analg. 2011;112:558–67.
- 53 Aeschlimann A, Buettner UW, Desmeules JA, de Stoutz ND, Eychmüller S, Limacher F, et al. Empfehlungen zur Opioïdtherapie chronischer Schmerzen. Teil 1. Schweiz Med Forum. 2005;5:1076–82; Teil 2. Schweiz Med Forum. 2005;5:1107–13.
- 54 Hänsel A, von Känel R. Opiattherapie bei chronischen, nicht-tumorbedingten Schmerzerkrankungen: sinnvoll oder unsinnig? Schweiz Med Forum. 2012;12:744–9.
- 55 Kalso E, Edwards JE, Moore A, McQuay HJ. Opioids in chronic non-cancer pain: systematic review of efficacy and safety. Pain. 2004;112:372–80.
- 56 Gomes T, Mamdani MM, Dhalla IA, Paterson JM, Juurlink DN. Opioid dose and drug-related mortality in patients with non-malignant pain. Arch Int Med. 2011;171:686–91.
- 57 Ballantyne JC. Opioid therapy: Is it appropriate in patients with noncancer pain? An evidence-based look at the issue? ASA Refresher Course. 2006;34:31–42.
- 58 Okie S. A flood of opioids, a rising tide of deaths. N Engl J Med. 2010;363:1981–3.
- 59 Bohnert AS, Valenstein M, Bair MJ, Ganoczy D, McCarthy JF, Ilgen MA, Blow FC. Association between opioid prescribing patterns and opioid overdose-related deaths. JAMA. 2011;305:1315–21.
- 60 Tavernise S. Ohio county losing its young to painkillers' grip. New York Times April 19, 2011.
- 61 Theiler R, Wyrsch B. Rationale Schmerztherapie – oder doch nicht? Schweiz Med Forum. 2012;12:645–51.
- 62 Woodcock J. A difficult balance – Pain management, drug safety, and the FDA. N Engl J Med. 2009;361:2105–7.
- 63 DGSS Leitlinien Kommission LONTS <http://www.awmf.org/leitlinien/detail>
- 64 Delleijn P. Are opioids effective in relieving neuropathic pain? Pain. 1999;80:453–62.
- 65 Koppert W, Ihmsen H, Körber N, Wehrfritz A, Sittl R, Schmelz, et al. Different profiles of buprenorphine-induced analgesia and antihyperalgesia in a human pain model. Pain. 2005;118:15–22.
- 66 Noble M, Treadwell JR, Tregeair SJ, Coates VH, Wiffen PJ, Akafomo C, et al. Long-term opioid management for chronic noncancer pain. Cochrane Database Syst Rev. 2010; 20:CD006605
- 67 Ballantyne JC, La Forge KS. Opioid dependence and addiction during opioid treatment of chronic pain. Pain. 2007;129:235–55.
- 68 Ross FB, Wallis SC, Smith MT. Co-administration of sub-antinociceptive doses of oxycodone and morphine produces marked antinociceptive synergy with reduced CNS side effects in rats. Pain. 2000;84:421–8.
- 69 Webster L, Richards P, Stern W, Kelen R. A double-blind, placebo-controlled study of dual-opioid treatment with the combination of morphine plus oxycodone in patients with acute postoperative pain. J Opioid Manag. 2010;6:1–12.
- 70 Tanaka M, Watanabe S, Ashimura H, Akioshi Y, Nishijima Y, Sato S, et al. Minimum effective combination dose of epidural morphine and fentanyl for posthysterectomy analgesia: A randomized, prospective, double-blind study. Anesth Analg. 1993;77:942–6.
- 71 Angst M, Clark JD. Opioid-induced hyperalgesia: a quantitative systematic review. Anesthesiology. 2006;104:570–87.
- 72 Hutchinson MR, Coats BD, Lewis SS, Zhang Y, Sprunger DB, Rezvani N, et al. Proinflammatory cytokines oppose opioid-induced acute and chronic analgesia. Brain Behav Immun. 2008;22:1178–89.

- 73 Daniell HW. Hypogonadism in men consuming sustained action oral opioids. *J Pain*. 2002;3:377–84.
- 74 Abs R, Verhelst, Meyaert J, van Buyten JP, Opsomer F, Adrianensen H, et al. Endocrine consequences of long-term intrathecal administration of opioids. *J Clin Endocrinol Metab*. 2000;85:2215–22.
- 75 Page G. The immune-suppressive effects of pain. *Adv Exp Med Biol*. 2003;521:117–25.
- 76 Gupta K, Kshirsagar S, Chang L, Schwartz R, Law PY, Yee D, et al. Morphine stimulates angiogenesis by activating proangiogenic and survival-promoting signalling and promotes breast tumor growth. *Cancer Research*. 2002;62:4491–8.
- 77 Mathew B, Lennon F, Siegler J, Mirzapozova T, Mambetsarieva N, Sammani S, et al. The novel role of the mu receptor in lung cancer progression: a laboratory investigation. *Anesth Analg*. 2011;112:558–67.
- 78 Smith TJ, Staats PS, Deer T, Stearns LJ, Rauck RL, Boortz-Marx RL, et al. Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: Impact on pain, drug-related toxicity, and survival. *J Clin Oncol*. 2002;20:4040–9.
- 79 <http://eapcnet.wordpress.com/2012/03/30/do-opioids-influence-cancer-growth-the-iahpc-perspective-3/>
- 80 Meissner W, Leyendecker P, Mueller-Lissner S, Nadstawek J, Hopp M, et al. A randomized controlled trial with prolonged – release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation. *Eur J Pain*. 2009;13:56–64.
- 81 Berde C, Nurko S. Opioid side effects –mechanism based therapy. *N Engl J Med*. 2008;358:22:2400–02.
- 82 Thomas J, Karver S, Cooney GA, Chamberlain BH, Watt CK, Slatkin NE, et al. MethylNaltrexone for opioid-induced constipation in advanced illness. *N Engl J Med*. 2008;358:2332–43.
- 83 Wolff BG, Michelassi F, Gerkin TM, Techner L, Gabriel K, Du W, et al. Alvimopan, a novel, peripherally acting mu opioid antagonist: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial of major abdominal surgery and postoperative ileus. *Ann Surg*. 2004;240:728–34.
- 84 Syrjala KL, Artherholt SB, Kurland BF, Langer SL, Roth-Roemer S, Elrod JB, et al. Prospective neurocognitive function over 5 years after allogeneic cell transplantation for cancer survivors compared with matched controls at 5 years. *J Clin Oncol*. 2011;29:2397–404.
- 85 Sjögren P, Olsen AK, Thomsen AB, Dahlberg J. Neuropsychological performance in cancer patients: the role of oral opioids, pain and performance status. *Pain*. 2000;86:237–45.
- 86 Sjögren P, Thomsen A, Olsen AK. Impaired neuropsychological performance in chronic non-malignant pain patients receiving long-term oral opioid therapy. *J Pain Symptom Manage*. 2000;19:100–08.
- 87 Kurita G, Sjögren P, Ekholm O, Kaasa S, Loge JH, Poviloniene I, et al. Prevalence and predictors of cognitive dysfunction in opioid-treated patients with cancer: a multinational study. *J Clin Oncol*. 2011;29:1297–303.
- 88 Kjellberg F, Tramer MR. Pharmacological control of opioid-induced pruritus: a quantitative systematic review of randomized trials. *Eur J Anaesth*. 2001;18:346–57.
- 89 Cohen SE, Ratner EF, Kreitzman TR, Archer JH, Mignano LR. Nalbuphine is better than naloxone for treatment of side effects after epidural morphine. *Anesth Analg*. 1992;75:747–52.
- 90 Gong QL, Hedner J, Bjorkmann R, Hedner T. Morphine-3-glucuronide may functionally antagonize morphine-6-glucuronide induced antinociception and ventilatory depression in the rat. *Pain*. 1992;48:249–55.
- 91 Angst MS, Bührer M, Lötsch J. Insidious intoxication after morphin treatment in renal failure: Delayed onset of morphine-6-glucuronide action. *Anesthesiology*. 2000;92:1473–6.
- 92 Filitz J, Griessinger N, Sittl R, Likar R, Schüttler J, Koppert W. Effects of intermittent hemodialysis on buprenorphine and norbuprenorphine plasma concentrations in chronic pain patients treated with transdermal buprenorphine. *Eur J Pain*. 2006;10:743–8.
- 93 Arzneimittel-Kompendium der Schweiz 2012 S. 53–56.
- 94 Gardner-Nix J, Mercandante S. The role of OROS hydromorphone in the management of cancer pain. *Pain Pract*. 2010;10:72–7.
- 95 Schröder W, De Vry J, Tzschenkne TM, Jahnel U, Christoph T. Differential contribution of opioid and noradrenergic mechanism to the antinociceptive and antihypersensitive efficacy of tapentadol in rat models of nociceptive and neuropathic pain. *Eur J Pain*. 2010;14:814–21.
- 96 Schwartz S, Etropolski M, Shapiro DY, Okamoto A, Lange R, Haeussler J, et al. Safety and efficacy of tapendadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial. *Curr Med Res Opin*. 2011;27:151–62.
- 97 Brinkers M, Petz T, Hoffmeyer D. Psychopharmaka in der Schmerztherapie – Spezielle Bedeutung der Antikonvulsiva und Neuroleptika in der Behandlung von Patienten mit chronischen Schmerzen. *Anästhesiol Intensivmed Notfallmed Schmerzther*. 2001;46:20–7.
- 98 Wörner J, Rukwied R, Konrad C. Co-Analgetika – heute und morgen. Eine rezeptorbasierte Übersicht analgetischer Therapieoptionen. *Anästhesiol Intensivmed Schmerzther*. 2009;44:736–44.
- 99 Domar AD, Moragianni VA, Ryley DA, Urato AC. The risks of selective serotonin reuptake inhibitor use in infertile women: a review of the impact on fertility, pregnancy, neonatal health and beyond. *Hum Reprod* 2012; Oct 31 (Epub ahead of print)
- 100 Clarke H, Bonin RP, Orser BA, Englesakis M, Wijeysundere DN, Katz J. The prevention of chronic postsurgical pain unsing gabapentin and pregabalin: a combined systematic review and meta-analysis. *Anesth Analg*. 2012;115:428–42.
- 101 Garcia de Paredes ML, del Moral Ganzales F, Martinez de Prado P, Marti Cirquian JL, Enrech Frances S, Cobo Dols M, et al. First evidence of oncologic neuropathic pain prevalence after screening 8615 cancer patients. *Ann Oncol*. 2011;22:924–30.
- 102 Molgaard-Nielsen D. Newer-generation antiepileptic drugs and the risk of major birth defects. *JAMA*. 2011;305:1996–02.
- 103 Jetté N, Lix LM, Metge CJ, Prior HJ, McChesney J, Leslie WD. Association of antiepileptic drugs with nontraumatic fractures: a population-based analysis. *Arch Neurol*. 2011;68:107–12.
- 104 Mercadante SI, Berchovich M, Casuccio A, Fulfaro F, Mangione S. A prospective randomized study of corticosteroids as adjuvant drugs to opioids in advanced cancer patients. *Am J Hosp Palliat Care*. 2007;24:13–9.
- 105 Bruera E, Roca E, Cedaro L, Carraro S, Chacon R. Action of methylprednisolone in terminal cancer patients: a prospective randomized double-blind study. *Cancer Treat Rep*. 1985;69:751–4.
- 106 Romundstad L, Breivik H, Niemi G, Helle A, Stubhaug A. Methylprednisolone intravenously 1 day after surgery has sustained analgesic and opioid-sparing effects. *Acta Anaesthesiol Scand*. 2004;48:1223–31.

- 107 Lipton A. Treatment of bone metastases and bone pain with bisphosphonates. *Support Ther.* 2007;4:92–100.
- 108 Walker K, Medhurst SJ, Kidd BL, Glatt M, Bowes M, Patel S, et al. Disease modifying and anti-nociceptive effects of the bisphosphonate zoledronic acid in a model of bone cancer pain. *Pain.* 2002;100(3):219–29.
- 109 Woo SB, Hellstein JW, Kalmar JR. Narrative review: bisphosphonates and osteonecrosis of the jaw. *Ann Intern Med.* 2006;144:753–61.
- 110 Petrenko AB, Yamakura T, Baba H, Shimoji K. The role of N-Methyl-D-Aspartate (NMDA) receptors in pain: a review. *Anesth Analg.* 2003;97:1108–16.
- 111 Weinbroum AA. A single small dose of postoperative ketamine provides rapid and sustained improvement in morphine analgesia in the presence of morphine-resistant pain. *Anesth Analg.* 2003;96:789–95.
- 112 Eilers H, PhilipLA, Philip EB, McKay WR, Schumacher MA. The reversal of fentanyl-induced tolerance by administration of “small-dose” ketamine. *Anesth Analg.* 2001;93:213–4.
- 113 McCartney CJL, Sinha A, Katz J. A qualitative systematic review of the role of N-Methyl-D-Aspartate receptor antagonists in preventive analgesia. *Anesth Analg.* 2004;98:1385–400.
- 114 Vranken JH, Dijkgraaf MGW, Kruis MR, van Dasselaar NT, van der Vegt MH. Iontophoretic administration of S(+)-ketamine in patients with intractable central pain: A placebo-controlled trial. *Pain.* 2005;118:224–31.
- 115 Böttcher S, Hoppe-Tichy T. Herstellung und Analytik eines Midazolam- und Ketamin-haltigen Nasensprays (Midaket-Nasenspray). *Krankenhauspharmazie.* 2000;21:618–21.
- 116 Vranken JH, Dijkgraaf MGW, Kruis MR, van Dasselaar NT, van der Vegt MH. Iontophoretic administration of S(+)-ketamine in patients with intractable central pain: A placebo-controlled trial. *Pain.* 2005;118:224–31.
- 117 Mercadante S, Arcuri E, Tirelli W, Casuccio A. Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: a randomized, controlled, double-blind crossover, double dose study. *J Pain Symptom Manage.* 2000;20:246–52.
- 118 Yang CY, Wong CS, Chang JY, Ho ST. Intrathecal ketamine reduces morphine requirements in patients with terminal cancer pain. *Can J Anaesth.* 1996;43:379–83.
- 119 Vranken JH, Troost D, Wegener JT, Kruis MR, van der Vegt MH. Neuropathological findings after continuous intrathecal administration of S(+)-Ketamine for the management of neuropathic cancer pain. *Pain.* 2005;117:231–5.
- 120 Pal HR, Berry N, Kumar R, Ray R. Ketamine dependence. *Anaesth Intensive Care.* 2002;30:382–4.
- 121 Kraft B, Frickey NA, Kaufmann RM, Reif M, Frey R, Gustorff B, et al. Lack of analgesia by oral standardized cannabis extract on acute inflammatory pain and hyperalgesia in volunteers. *Anesthesiology.* 2008;109:101–10.
- 122 Naef M, Curatolo M, Petersen-Felix S, Arendt-Nielsen L, Zbinden A, Brenneisen R. The analgesic effect of oral delta-9-tetrahydrocannabinol (THC), morphine, and a morphine combination in healthy subjects under experimental pain conditions. *Pain.* 2003;105:79–88.
- 123 Frank B, Serpell MG, Hughes J, Matthews JN, Kapur D. Comparison of analgesic effects and patient tolerability of nabilon and dihydronorepinephrine for chronic neuropathic pain: randomized, crossover, double blind study. *BMJ.* 2008;336:199–201.
- 124 Attal N, Brasseur L, Guirimand D, Clermont-Gnamié S, Atlami S, et al. Are oral cannabinoids safe and effective in refractory neuropathic pain? *Eur J Pain.* 2004;8:173–7.
- 125 Beaulieu P, Ware M. Reassessment of the role of cannabinoids in the management of pain. *Curr Opin Anaesthesiol.* 2007;20:473–7.
- 126 Abrahams DI, Jay CA, Shade SB, Vizoso H, Reda H, Press S, et al. Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial. *Neurology.* 2007;68:515–21.
- 127 Desroches J, Beaulieu P. The cannabinoid system and pain: a new therapeutic avenue? *Rev Med Suisse.* 2008;4:1505–6.
- 128 Bradley SG, Rowbotham MC, Perander J, Friedmann E. Topical lidocaine patch relieves postherpetic neuralgia more effectively than a vehicle topical patch: results of an enriched enrolment study. *Pain.* 1999;80:533–8.
- 129 Derry S, Moore RA, Rabbie R. Topical NSAIDs for chronic musculoskeletal pain in adults. *Cochrane Database Syst Rev* 2012; Sep 12;9:CD007400.doi
- 130 Wachtel RE. Translational vignette Capsaicin. *Reg Anesth Pain Med.* 1999;24:361–3.
- 131 Anand P, Bley K. Topical capsaicin for pain management: Therapeutic potential and mechanisms of action of the new high-concentration capsaicin 8% patch. *Br J Anaesth.* 2011;107:490–502.
- 132 Esser MJ, Sawynok J. Acute amitriptyline in a rat model of neuropathic pain: differential symptoms and route effects. *Pain.* 1999;80:643–53.
- 133 Lynch ME, Clark AJ, Sawynok J, Sullivan MJL. Topical 2% Amitriptyline and 1% Ketamine in neuropathic pain syndromes. A randomized, double-blind, placebo-controlled trial. *Anesthesiology.* 2005;103:140–6.
- 134 Ho KY, Huh BK, White WD, Yeh CC, Miller EJ. Topical amitriptyline versus lidocaine in the treatment of neuropathic pain. *Clin J Pain.* 2008;24:51–5.
- 135 Finch PM, Knudsen L, Drummond PD. Reduction of allodynia in patients with complex regional pain syndrome: a double-blind placebo-controlled trial of topical ketamine. *Pain.* 2009;146:18–25.
- 136 Gaspar M, Bovaira M, Carrera-Hueso FJ, Querol M, Jiménez A, Moreno L. Efficacy of a topical treatment protocol with dimethyl sulfoxide 50% in type 1 complex regional pain syndrome. *Farm Hosp.* 2012;36:385–91.
- 137 Poonawala T, Levay BK, Hebbel RP, Gupta K. Opioids heal ischemic wounds in the rat. *Wound Rep Reg.* 2005;13:165–74.
- 138 Huptas L, Rompoti N, Herbig S, Körber A, Klode J, Schadendorf D, Dissemond J. Schmerzreduktion bei Patienten mit chronischem Ulcus cruris durch ein neu entwickeltes Morphingel. *Hautarzt.* 2011;62:280–6.
- 139 Meidan VM, Michniak BB. Emerging technologies in transdermal therapeutics. *Am J Ther.* 2004;11:312–6.